PT - JOURNAL ARTICLE AU - Dario Bongiovanni AU - Constantin Kühl AU - Sabine Bleiziffer AU - Lynne Stecher AU - Felix Poch AU - Martin Greif AU - Julinda Mehilli AU - Steffen Massberg AU - Norbert Frey AU - Rüdiger Lange AU - Karl-Ludwig Laugwitz AU - Gerhard Schymik AU - Derk Frank AU - Christian Kupatt TI - Emergency treatment of decompensated aortic stenosis AID - 10.1136/heartjnl-2016-311037 DP - 2018 Jan 01 TA - Heart PG - 23--29 VI - 104 IP - 1 4099 - http://heart.bmj.com/content/104/1/23.short 4100 - http://heart.bmj.com/content/104/1/23.full SO - Heart2018 Jan 01; 104 AB - Objective The optimal treatment of patients with acute and severe decompensation of aortic stenosis is unclear due to recent advances in transcatheter interventions and supportive therapies. Our aim was to assess the early outcome of emergency transcatheter aortic valve implantation (eTAVI) versus emergency balloon aortic valvuloplasty (eBAV) followed by TAVI under elective circumstances.Methods Emergency conditions were defined as: cardiogenic shock with requirement of catecholamine therapy, severe acute dyspnoea (NYHA IV), cardiac resuscitation or mechanic respiratory support. The data were collected according to the Valve Academic Research Consortium 2 (VARC-2) criteria.Results In five German centres, 23 patients (logistic Euroscore 37.7%±18.1) underwent eTAVI and 118 patients underwent eBAV (logistic Euroscore 35.3%±20.8). In the eTAVI group, immediate procedural mortality was 8.7%, compared with 20.3% for the eBAV group (p=0.19). After 30 days, cardiovascular mortality for the eTAVI group was 23.8% and for the eBAV group 33.0% (p=0.40). Analyses adjusting for potential confounders did not provide evidence of a difference between groups. Of note, the elective TAVI performed after eBAV (n=32, logistic Euroscore 25.9%±13.9) displayed an immediate procedural mortality of 9.4% and a cardiovascular mortality after 30 days of 15.6%. Major vascular complications were significantly more likely to occur after eTAVI (p=0.01) as well as stroke (p=0.01).Conclusion In this multicentre cohort, immediate procedural and 30-day mortality of eTAVI and eBAV were high, and mortality of secondary TAVI subsequent to eBAV was higher than expected. Randomised study data are required to define the role of emergency TAVI in tertiary care centres with current device generations.